program information
This unique industry event is designed to help companies active in the self-insurance/captive insurance marketplace better understand common growth strategies made possible by corporate financial transactions (mergers, acquisitions, capitalizations, etc.). Additionally, attendees will learn more about important market factors affecting the self-insurance marketplace and the implications for corporate growth strategies. In addition to targeted educational content and the ability to engage with other members with similar interests, attendees will have the opportunity to connect with important sources of capital, including private equity sponsors and strategic investors.
FORUM LINKS
Wednesday, May 29, 2024
3:00 p.m. to 6:30 p.m.
Registration Open
5:00 p.m. to 6:30 p.m.
Welcome Reception
Thursday, May 30, 2024
7:00 a.m. to 8:00 a.m.
Continental Breakfast
8:00 a.m. to 8:30 a.m.
Welcome & SIIA Cell & Gene Therapy Task Force Update
SPEAKER:
 |
Shaun Peterson
Chairman
SIIA Cell & Gene Task Force
8:30 a.m. to 9:15 a.m.
Approval Pathways and Effects on Coverage
With the acceleration of approved treatments, self-insured employers must now make more CGT coverage decisions at a faster pace. This session will address how and why accelerated approval pathways exist and how that impacts medical policy and key coverage decision considerations.
SPEAKER:
 |
Rachael Anatol, Ph.D.
Deputy Super Office Director
Office of Therapeutic Products (OTP),
Center for Biologics Evaluation and Research (CBER),
Federal Drug Administration
9:15 a.m. to 10:30 a.m.
The Manufacturers Perspective
This panel discussion will feature some of the leading CGT manufacturers with products on the market who will provide an overview of how the launch of their products are going with over a year since approval for each product. There will also be a brief pipeline and exposure update from NEWDIGS. The panel will also address pricing implications, value-based payments, warranties, and patient access considerations.
MODERATOR:
 |
Mark Trusheim
Strategic Director
NEWDIGS, Center for Biomedical System Design
Tufts Medical Center
SPEAKERS:
 |
Jay Newman
SVP & Head of Commercial Development,
Pricing & Reimbursement
Spark Therapeutics, Inc
 |
LeeAnna Hoskins
VP Payer Access & Reimbursement
Sarepta Therapeutics
 |
Susan Serrano
Senior Director, Contracting and Payer Marketing
bluebird bio
10:30 a.m. to 10:45 a.m.
Networking Break
10:45 a.m. to Noon
Marketplace Solutions for Self-Insured Payers – What’s Working?
Like it has done when faced with past challenges, the self-insurance industry is adapting to evolving CGT realities with companies bringing new solutions to market and working to develop additional solutions for future introduction. Without advertising specific company products/services, this session will discuss the type of market solutions available to self-insured payers today, what may be coming soon, and the gaps that have yet to be addressed as well as the challenges that are still out there.
MODERATOR:
 |
Richard Fleder
CEO
ELMCRx Solutions
SPEAKERS:
 |
Ben Dewar
Senior Vice President
ParetoHealth
 |
Brooks Wildasin
Co-Founder & Chief Underwriting Officer
OutcomeRx Insurance Management Services, LLC.
 |
Ramesh Jayasuriya
Head of Digital Health
Evio
 |
Joe Sabol
Senior Vice President
DW Van Dyke
Noon to 1:00 p.m.
Hosted Lunch
1:00 p.m. to 1:45 p.m.
Patient Perspectives with Cell & Gene Therapy
While there are certainly many important business, regulatory, and clinical CGT details that warrant ongoing discussion, the patient is at the center of all the stakeholders in the room. This session will be put an actual face and voice to how CGT treatment can change lives. Our speakers will address the excitement and challenges this community faces in light of the new approved therapies.
SPEAKERS:
 |
Rae Blaylark
President & CEO
Sickle Cell Foundation of Minnesota
 |
Erica Barnes
Executive Director
Minnesota Rare Disease Counsel
1:45 p.m. to 3:00 p.m.
CGT & Financial Risk Transfer Considerations
Given the large price tags associated with many CGTs, the self-insurance industry Is grappling with various financial risk transfer strategies to enable employers to cover important new treatments. This panel will discuss what is happening now in the marketplace and where the thought leaders see things going. Perspectives include stop-loss, MGU, reinsurance, and captive insurance.
MODERATOR:
 |
Raj Gulati
Senior Vice President
Risk Strategies
SPEAKERS:
 |
Theresa Galizia
SVP & CUO
Berkley Accident & Risk
 |
Mike Remeika
President
Skyward Accident & Health
 |
Thomas Braun
Senior Broker
Lockton Companies
 |
Crystal Kauder, ASA, MAAA
Chief Pricing Actuary, US Health
PartnerRe America Insurance Company
3:00 p.m. to 3:15 p.m.
Networking Break
3:15 p.m. to 4:15 p.m.
Provider Experience
As new therapies receive approval, physicians and facilities face several challenges that may affect patient access, including administrative policies from payers, payment policy issues, and regulatory obstacles. Furthermore, physicians are committed to offering lifesaving care despite these challenges, while also addressing concerns about sustainability. This panel will discuss the various issues that physicians and healthcare facilities encounter as they strive to deliver patient-centered care without incurring substantial receivables or facing uncertainties regarding payment.
MODERATOR:
 |
Stephanie Farnia
Principal
Nimitt Consulting
SPEAKERS:
 |
Claire White, MSN, RN
Policy Analyst
Cellular Therapy & Transplant Section
Children’s Hospital of Philadelphia
 |
Stephan Grupp, MD, PhD
Medical Director
Cell and Gene Therapy Lab
Children’s Hospital of Philadelphia
 |
Amy Emmert, MScPH
Executive Director, External Affairs
HSCT & Cellular Therapy Service Line
Dana-Farber Cancer Institute
4:15 p.m. - 5:00 p.m.
Share, Ask & Answer
We’ve reserved the last hour of the program for a moderated group discussion where attendees will be encouraged to engage with each other regarding what they have heard during the day of presentations and related conversations.
MODERATOR:
 |
Ashley Hume
Chief Commercial Officer
Emerging Therapy Solutions
